{"id":"NCT02474355","sponsor":"AstraZeneca","briefTitle":"Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC","officialTitle":"Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy With an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-18","primaryCompletion":"2019-04-18","completion":"2019-04-18","firstPosted":"2015-06-17","resultsPosted":"2021-10-25","lastUpdate":"2021-11-11"},"enrollment":3017,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lung Cancer"],"interventions":[{"type":"PROCEDURE","name":"T790M+ Testing","otherNames":[]},{"type":"PROCEDURE","name":"Baseline Visit Blood & Urine Testing","otherNames":[]},{"type":"PROCEDURE","name":"Baseline ECG","otherNames":[]},{"type":"PROCEDURE","name":"Visual Slit-Lamp Testing","otherNames":[]},{"type":"DRUG","name":"AZD9291 Dosing","otherNames":[]}],"arms":[{"label":"AZD9291","type":"EXPERIMENTAL"}],"summary":"The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From the date of first dose of Osimertinib until the date of death (due to any cause) or last participant contact [up to 43 months]","effectByArm":[{"arm":"Osimertinib","deltaMin":22.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":201,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Denmark","Ireland","Italy","Saudi Arabia","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["37316692","36656302","35050743"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5160C00022&amp;attachmentIdentifier=dd920aaa-edfe-410c-9fae-e649b1f11351&amp;fileName=223048_D5160C00022_CSP_Final_(deidentified).pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5160C00022&amp;attachmentIdentifier=e2241d73-0d0f-4439-b968-f6ed09f8d283&amp;fileName=223048_D5160C00022_SAP_and_Addendum_Final_(deidentified).pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":657,"n":3014},"commonTop":["Electrocardiogram QT prolonged","Diarrhoea","Thrombocytopenia","Platelet count decreased","Neutropenia"]}}